Sera Prognostics, Inc., (SERA) News

Sera Prognostics, Inc., (SERA): $9.80

0.24 (-2.39%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

D

Add SERA to Watchlist
Sign Up

Industry: Medical - Services

Industry

C

Ranked

#63 of 67

in industry

Filter SERA News Items

SERA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SERA News Highlights

  • SERA's 30 day story count now stands at 4.
  • Over the past 5 days, the trend for SERA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about SERA are MET and TOP.

Latest SERA News From Around the Web

Below are the latest news stories about SERA PROGNOSTICS INC that investors may wish to consider to help them evaluate SERA as an investment opportunity.

Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy

Does Sera Prognostics, Inc. (SERA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | December 11, 2023

While institutions invested in Sera Prognostics, Inc. (NASDAQ:SERA) benefited from last week's 183% gain, retail investors stood to gain the most

Key Insights Significant control over Sera Prognostics by retail investors implies that the general public has more...

Yahoo | December 7, 2023

Stocks Edge Higher On Hopes Of Soft Economic Landing

Easing labor costs, rising productivity, and a cooling labor market are supporting Wall Street this afternoon.

TalkMarkets.com | December 6, 2023

Why Is Sera Prognostics (SERA) Stock Up 260% Today?

With an oversight board recommending Sera Prognostics halt its clinical study for efficacy, SERA stock soared on the positive implications.

Josh Enomoto on InvestorPlace | December 6, 2023

SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stoppi

Yahoo | December 6, 2023

SERA PROGNOSTICS TO PRESENT AT 35TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming 35th Annual Piper Sandler Healthcare Conference to be held November 28-30, 2023 in New York City.

Yahoo | November 22, 2023

Sera Prognostics, Inc. (NASDAQ:SERA) Q3 2023 Earnings Call Transcript

Sera Prognostics, Inc. (NASDAQ:SERA) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2023 results. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Peter […]

Yahoo | November 12, 2023

Sera Prognostics Inc (SERA) Reports Q3 2023 Financial Results: Revenue Declines as Cost ...

Management Focuses on Commercial Strategy and Cost Efficiency

Yahoo | November 8, 2023

SERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2023 ended September 30, 2023.

Yahoo | November 8, 2023

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2023 Financial Results on November 8, 2023

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2023 financial results on Wednesday, November 8, 2023, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern

Yahoo | October 25, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!